Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul;10(7):3093–3105. doi: 10.21037/tlcr-21-197

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2021 Translational Lung Cancer Research. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

Treatment duration in cycles of therapy for 1st and 2nd line treatment in the subgroup of patients treated by platinum + pemetrexed + pembrolizumab 1st line (N=50). 1st line treatment left side is divided into platinum based CTx+ICI, maintenance therapy with CTx+ICI and maintenance therapy with ICI monotherapy. D+R treatment is presented at the right side. Arrows define patients with D+R ongoing, X defines patients with an underlying KRAS mutation.